164 related articles for article (PubMed ID: 26913406)
1. [HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling Pathway].
Chen KK; He ZM; Ding BH; Chen Y; Zhang LJ; Yu L; Gao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):117-21. PubMed ID: 26913406
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells.
Wang J; Li Y; Sun W; Liu J; Chen W
Hematology; 2018 Oct; 23(9):620-625. PubMed ID: 29566599
[TBL] [Abstract][Full Text] [Related]
3. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
[TBL] [Abstract][Full Text] [Related]
4. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
5. [Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways].
Fu Y; Zhang Y; Zhang F; Liu J; Gui R
Zhonghua Xue Ye Xue Za Zhi; 2015 Sep; 36(9):780-4. PubMed ID: 26462781
[TBL] [Abstract][Full Text] [Related]
6. [Influence of Co-inhibiting mTORC2 and HSP90 on Proliferation Apoptosis of Multiple Myeloma Cells].
Chen KK; Chen Y; He ZM; Zhou LT; Zhang LJ; Song LX; Ding BH; Wang CL; Yu L; Zhou JW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1086-90. PubMed ID: 27531779
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.
Liang GH; Liu N; He MT; Yang J; Liang ZJ; Gao XJ; Rahhal AH; He QY; Zhang HT; Zha ZG
J Cell Biochem; 2018 Jan; 119(1):948-959. PubMed ID: 28681940
[TBL] [Abstract][Full Text] [Related]
9. [Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG].
Wang NN; Li ZH; Tao YF; Xu LX; Pan J; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):672-80. PubMed ID: 27342489
[TBL] [Abstract][Full Text] [Related]
10. [Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901].
Chen M; Xu J; Zhao J
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):271-5. PubMed ID: 23443787
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
12. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
13. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
14. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
15. HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.
Mohammadi A; Yaghoobi MM; GholamhoseynianNajar A; Kalantari-Khandani B; Sharifi H; Saravani M
Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):62-67. PubMed ID: 27894402
[TBL] [Abstract][Full Text] [Related]
16. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
[TBL] [Abstract][Full Text] [Related]
17. [Effects of 17-AAG on the proliferation and apoptosis of human lung cancer A549 and H446 cells].
Niu B; Lin J; Feng T
Zhonghua Jie He He Hu Xi Za Zhi; 2015 Apr; 38(4):267-72. PubMed ID: 26268232
[TBL] [Abstract][Full Text] [Related]
18. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
19. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
Cervantes-Gomez F; Nimmanapalli R; Gandhi V
J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 Inhibitor, 17-AAG, Influences the Activation and Proliferation of T Lymphocytes via AKT/GSK3β Signaling in MRL/lpr Mice.
Hong LJ; Chen AJ; Li FZ; Chen KJ; Fang S
Drug Des Devel Ther; 2020; 14():4605-4612. PubMed ID: 33149557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
